Episode

Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review

Podcast
Hematologic Oncology Update
Published
Jan 21, 2026
Duration seconds
3672
Processing state
not_requested
Canonical source
https://hematologic-oncology.captivate.fm/episode/5606-ashbispecificslymphoma25
Audio
https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/2a2c2fe2-09a8-435e-b24d-9c07220c6366.mp3
JSON
/v1/public/podcasts/hematologic-oncology-update-916423/episodes/bispecific-antibodies-in-the-management-of-lymphoma-ash-2025-review
Markdown
/podcast/hematologic-oncology-update-916423/bispecific-antibodies-in-the-management-of-lymphoma-ash-2025-review.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/bispecific-antibodies-in-the-management-of-lymphoma-ash-2025-review/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/hematologic-oncology-update-916423/bispecific-antibodies-in-the-management-of-lymphoma-ash-2025-review.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma. CME information and select publications here .